Nothing Special   »   [go: up one dir, main page]

DK1513551T3 - Vaccination med immun-isolerede celler, der producerer en immunomodulator - Google Patents

Vaccination med immun-isolerede celler, der producerer en immunomodulator

Info

Publication number
DK1513551T3
DK1513551T3 DK03759977.6T DK03759977T DK1513551T3 DK 1513551 T3 DK1513551 T3 DK 1513551T3 DK 03759977 T DK03759977 T DK 03759977T DK 1513551 T3 DK1513551 T3 DK 1513551T3
Authority
DK
Denmark
Prior art keywords
immunomodulator
vaccination
cells producing
relates
immune
Prior art date
Application number
DK03759977.6T
Other languages
English (en)
Inventor
Nicolas Mach
Original Assignee
Maxivax Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxivax Sa filed Critical Maxivax Sa
Application granted granted Critical
Publication of DK1513551T3 publication Critical patent/DK1513551T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03759977.6T 2002-06-17 2003-06-17 Vaccination med immun-isolerede celler, der producerer en immunomodulator DK1513551T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02013249A EP1374893A1 (en) 2002-06-17 2002-06-17 Vaccination with immuno-isolated cells producing an immunomodulator
PCT/EP2003/007140 WO2003105895A1 (en) 2002-06-17 2003-06-17 Vaccination with immuno-isolated cells producing an immunomodulator

Publications (1)

Publication Number Publication Date
DK1513551T3 true DK1513551T3 (da) 2010-03-08

Family

ID=29716769

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09175526.4T DK2147682T3 (da) 2002-06-17 2003-06-17 Vaccination med immunisolerede celler til fremstilling af en immunmodulator
DK03759977.6T DK1513551T3 (da) 2002-06-17 2003-06-17 Vaccination med immun-isolerede celler, der producerer en immunomodulator

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09175526.4T DK2147682T3 (da) 2002-06-17 2003-06-17 Vaccination med immunisolerede celler til fremstilling af en immunmodulator

Country Status (8)

Country Link
US (3) US20060024318A1 (da)
EP (3) EP1374893A1 (da)
AT (1) ATE447968T1 (da)
AU (1) AU2003246369A1 (da)
DE (1) DE60330004D1 (da)
DK (2) DK2147682T3 (da)
ES (2) ES2560105T3 (da)
WO (1) WO2003105895A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8180920B2 (en) * 2006-10-13 2012-05-15 Rgb Networks, Inc. System and method for processing content
WO2009125332A1 (en) * 2008-04-07 2009-10-15 Peter Bromley New and safe procedure for immunization against infectious diseases agents
US8551749B2 (en) 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
ES2893750T3 (es) * 2015-09-25 2022-02-10 Maxivax Sa Vacuna que comprende células inmunoaisladas que producen un inmunomodulador
WO2018044888A1 (en) * 2016-08-29 2018-03-08 Chen James C Tumor vaccination systems, devices, and methods
US20230272334A1 (en) * 2020-07-27 2023-08-31 Arizona Board Of Regents On Behalf Of Arizona State University Artificial placenta vaccine for organ transplantation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5955095A (en) * 1992-04-22 1999-09-21 Brown University Research Foundation Microporous macrocapsules
TNSN93075A1 (fr) * 1992-07-08 1994-03-17 Schering Corp Utilisation de gm-csf comme adjuvant pour vaccin
WO1995016464A1 (en) * 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
CA2267977A1 (en) 1996-10-16 1998-04-23 Matthew G. Ewend Cytokine enhanced immunotherapy for brain tumors
DE69838324T2 (de) 1997-02-05 2008-05-15 Bystryn, Jean-Claude Ph-sensitive liposomen und andere typen immunomodulatoren enthaltender gekapselter impfstoffe sowie herstellungs- und anwendungsverfahren dafür
EP1053301B1 (en) * 1998-02-02 2004-04-21 The Johns Hopkins University School Of Medicine A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
US7250291B1 (en) * 1998-08-07 2007-07-31 Dana-Farber Cancer Institute Tumor antigens and uses thereof
CA2362578A1 (en) * 1999-02-09 2000-08-17 Kam Leong Tumor vaccines
EP1326968B1 (en) * 2000-10-12 2007-04-18 Agency for Science, Technology and Research Non-disruptive three-dimensional culture and harvest system for anchorage-dependent cells
FR2822707A1 (fr) * 2001-04-03 2002-10-04 Neurotech Association d'un antigene tumoral et d'un systeme de delivrance d'une cytokine ou d'une chemokine a des fins d'immunotherapie du cancer
US20050118425A1 (en) * 2002-05-07 2005-06-02 Childs Ronald F. Microcapsules containing biomedical materials

Also Published As

Publication number Publication date
EP1513551A1 (en) 2005-03-16
EP2147682B1 (en) 2015-11-11
DE60330004D1 (de) 2009-12-24
US20140341982A1 (en) 2014-11-20
AU2003246369A1 (en) 2003-12-31
ES2335490T3 (es) 2010-03-29
US20080107686A1 (en) 2008-05-08
US9814682B2 (en) 2017-11-14
EP2147682A2 (en) 2010-01-27
EP1513551B1 (en) 2009-11-11
EP2147682A3 (en) 2012-07-25
DK2147682T3 (da) 2016-02-01
ES2560105T3 (es) 2016-02-17
WO2003105895A1 (en) 2003-12-24
ATE447968T1 (de) 2009-11-15
US20060024318A1 (en) 2006-02-02
EP1374893A1 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
HK1083635A1 (en) Animal protein free media for cultivation of cells
WO2004058157A3 (en) Yeast-based vaccines as immunotherapy
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
MX9306841A (es) Vacuna a base de ureasa contra la infeccion por helicobacter en mamiferos.
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
WO2001095919A3 (en) A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
ATE461709T1 (de) Choline-bindende proteine derivate aus pneumokoken als impfstoff
EP2368573A3 (en) Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CY1113044T1 (el) Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων
FI970799A0 (fi) Mutanttientoroksiini, joka on tehokas ei-toksinen oraalinen adjuvantti
EP2385059A3 (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
BR0206312A (pt) Composição de vacina, uso sobrenadante de cultura celular de escherichia coli enteroemorrágica (ehec), e, métodos para a geração de uma resposta imunológica em um mamìfero contra um antìgeno de escherichia coli enteroemorrágica (ehec) secretado, e 0157:h7 enteroemorrágica (ehec 0157:h7) secretado, e para a redução da colonização de escherichia coli enteroemorrágica (ehec) em um ruminante
DK1513551T3 (da) Vaccination med immun-isolerede celler, der producerer en immunomodulator
ATE441420T1 (de) Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
ATE460943T1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
JP2008512491A5 (da)
EP1734992A4 (en) IMPROVED VACCINES AT FCV INACTIVE
WO2004002412A3 (en) A method and composition to elicit an effective autologous antitumoral immune response in a patient
ATE399794T1 (de) Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
PL358081A1 (en) Inclusion bodies as antigenes in oral immunization of animals
WO2003054176A3 (en) Preparation of vaccines using photosensitizer and light
DK1204421T3 (da) Stressprotein-peptidkomplekser som vacciner mod intracellulære patogener
DK1597274T3 (da) hsp60 fra Arthrobacter